机构：[a]The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, China[b]Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong[c]Biological Resource Centre, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[d]Department of Neurology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China[e]Department of Pediatrics, Masonic Cancer Center and Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA
Non-alcoholic fatty liver disease (NAFLD) is becoming an epidemic disease in adults and children worldwide. Importantly, there are currently no approved treatments available for NAFLD. This study aims to investigate the potential applications of sodium tanshinone IIA sulfonate (STS) on improving the NAFLD condition using both in vitro and in vivo approaches. The results showed that STS markedly inhibited lipid accumulation in oleic acid (OA) and palmitic acid (PA) treated HepG2 and primary immortalized human hepatic (PIH) cells. STS suppressed lipogenesis by inhibiting expression of sterol regulatory element binding transcription factor 1 (SREBF1), fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD). In addition, STS reduced inflammation in cells treated with OA-PA, shown by decreased transcriptional levels of tumor necrosis factor (TNF), transforming growth factor beta 1 (TGFB1) and interleukin 1 beta (IL1B). Consistently, protective effects on hepatic steatosis in db/db mice were observed after STS administration, demonstrated by decreased lipid accumulation in mouse hepatocytes. This protective effect might be associated with STS induced activation of sirtuin 1 (SIRT1)/protein kinase AMP-activated catalytic subunit alpha 1 (PRKAA1) pathways. Our findings suggest a potential therapeutic role for STS in the treatment of NAFLD.
基金：
This study was supported by The Shenzhen Science and Technology
Innovation Commission (JCYJ20170413154748190); Research Grants
Council Collaborative Research Fund Scheme (C5012-15E), Hong Kong
SAR Government; and the Department of Applied Biology and Chemical
Technology, The Hong Kong Polytechnic University, Hong Kong SAR
(G-YBTA).
基金编号：JCYJ20170413154748190
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|3 区医学
小类|3 区医学：研究与实验3 区药学
最新[2025]版：
大类|2 区医学
小类|2 区医学：研究与实验2 区药学
JCR分区：
出版当年[2017]版：
Q2PHARMACOLOGY & PHARMACYQ2MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
第一作者机构：[a]The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, China[b]Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong
共同第一作者：
通讯作者：
通讯机构：[a]The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, China[b]Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong
推荐引用方式(GB/T 7714)：
Xiao-Xiao Li,Xin-Yi Lu,Shi-Jie Zhang,et al.Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation[J].BIOMEDICINE & PHARMACOTHERAPY.2019,111:68-75.doi:10.1016/j.biopha.2018.12.019.
APA：
Xiao-Xiao Li,Xin-Yi Lu,Shi-Jie Zhang,Amy P. Chiu,Lilian H. Lo...&Vincent W. Keng.(2019).Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation.BIOMEDICINE & PHARMACOTHERAPY,111,
MLA：
Xiao-Xiao Li,et al."Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation".BIOMEDICINE & PHARMACOTHERAPY 111.(2019):68-75
